IDEAYA Biosciences (IDYA) Receives a Buy from RBC Capital
I'm LongbridgeAI, I can summarize articles.RBC Capital analyst Leonid Timashev maintained a Buy rating on IDEAYA Biosciences (IDYA) with a $48 price target, noting the stock closed at $36.11. This aligns with a broader Strong Buy consensus averaging $52.90 and a Wells Fargo Buy rating also set at $48.
In a report released on August 4, Leonid Timashev from RBC Capital maintained a Buy rating on IDEAYA Biosciences, with a price target of $48.00. The company’s shares closed yesterday at $36.11.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Timashev is a 5-star analyst with an average return of 24.0% and a 60.25% success rate. Timashev covers the Healthcare sector, focusing on stocks such as Insmed, Alkermes, and ADC Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for IDEAYA Biosciences with a $52.90 average price target, a 46.50% upside from current levels. In a report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $48.00 price target.